Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial
Andreas Glenthøj(University of Copenhagen), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Erin Zagadailov(AbbVie (United States)), Vanessa Beynon(Agios Pharmaceuticals (United States)), Abdulafeez Oluyadi(Agios Pharmaceuticals (United States)), John B. Porter(Royal London Hospital), Eduard J. van Beers(Utrecht University), Kevin H.M. Kuo(University Health Network), Hanny Al‐Samkari(Harvard University), Sarah Gheuens(Biogen (United States)), Frederic Galactéros(Inserm), Peter Hawkins(Agios Pharmaceuticals (United States)), Vip Viprakasit(Siriraj Hospital), Satheesh Chonat(Emory University), Rengyi Xu(Agios Pharmaceuticals (United States))
Cited by 49
Related Papers
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309